RNA base editing for the treatment of Alpha-1 antitrypsin deficiency

Prashant Monian

Senior Scientist II, Biology

May 17, 2023

26th Annual ASGCT meeting, May 16-20, 2023

Disclosures

Prashant Monian, Chikdu Shivalila, Genliang Lu, Keith Bowman, Marissa Bylsma, Michael Byrne, Megan Cannon, Jigar Desai, Alyse Faraone, Frank Favaloro, Anamitra Ghosh, Jack Godfrey, Nidia Hernandez, Naoki Iwamoto, Tomomi Kawamoto, Jayakanthan Kumarasamy, Pachamuthu Kandasamy, Anthony Lamattina, Muriel Lemaitre, Amber Lindsey, Fangjun Liu, Richard Looby, Khoa Luu, Jake Metterville, Ik-Hyeon Paik, Qianli Pan, Tom Pu, Erin Purcell-Estabrook, Jeanette Rheinhardt, Mamoru Shimizu, Kuldeep Singh, Stephany Standley, Carina Thomas, Snehlata Tripathi, Hailin Yang, Ryan Yordanoff, Yuan Yin, Hui Yu, Padma Narayanan, Paloma H. Giangrande, Chandra Vargeese

- All authors are employees of Wave Life Sciences

Forward-looking statements

This document contains forward-looking statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of operations, preclinical and clinical studies, business strategies, research and development plans, collaborations and partnerships, regulatory activities and timing thereof, competitive position, potential growth opportunities, use of proceeds and the effects of competition are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause the actual results, performance or achievements of Wave Life Sciences Ltd. (the "Company") to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this presentation are only predictions. The Company has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that it believes may affect the Company's business, financial condition and results of operations. These forward-looking statements speak only as of the date of this presentation and are subject to a number of risks, uncertainties and assumptions, including those listed under Risk Factors in the Company's Form 10-K and other filings with the SEC, some of which cannot be predicted or quantified and some of which are beyond the Company's control. The events and circumstances reflected in the Company's forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, the Company operates in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that the Company may face. Except as required by applicable law, the Company does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

AIMers: A-to-I RNA editing oligonucleotides

GalNAc-mediated delivery



Optimize AIMer design

- ✓ Substrate learnings from biology and structures
- ✓ Applied to oligonucleotides
- ✓ Applied PRISM™ chemistry



WAVE LIFE SCIENCES

[1]Woolf *et al.*, 1995 *Proc Natl Assoc Sci* 92:8298-8302;
Monian *et al.*, 2022 *Nature Biotech* doi: 10.1038.s41587-022-01225-1

SERPINA1 Z mutation: The most common cause of Alpha-1 antitrypsin deficiency (AATD)



AAT is an **acute phase protein** predominately produced by hepatocytes

Serum AAT protects lungs against neutrophil elastase

Gain-of-function and loss-of-function disease

Liver Disease

Fibrosis → Cirrhosis → Hepatocellular Carcinoma



E342K mutation causes AAT proteotoxic stress, leading to progressive liver disease



Lung Disease

Emphysema Bronchiectasis

Low serum AAT leads to lung disease

WAVE LIFE SCIENCES

Strnad *et al.*, 2020 *N Engl J Med* 382:1443-55; Stoller et al., 1993 *Alpha-1 Antitrypsin Deficiency* GeneReviews

RNA editing is uniquely suited to address the therapeutic goals of AATD

Wave ADAR editing approach potentially addresses all treatment goals:

1) Restore circulating, functional wild-type M-AAT

2) Reduce Z-AAT protein aggregation in liver

3) Retain M-AAT physiological regulation



M-AAT reaches lungs to protect from proteases



Wild-type M-AAT protein replaces Z-AAT with RNA correction



M-AAT secretion into bloodstream



Alternative approaches address only a subset of treatment goals:

Standard of care: weekly IV protein augmentation *(11 µM) addresses only lung manifestations*

siRNA *approaches address only liver disease*

Small molecule *approaches may address the lung and liver but do not restore wild-type M-AAT*

~200K people in US and EU with mutation in *SERPINA1* Z allele (PI*ZZ)

WAVE LIFE SCIENCES

AAT: Alpha-1 antitrypsin Strnad *et al.*, 2020 *N Engl J Med* 382:1443-55; Blanco *et al.*, 2017 *Int J Chron Obstruct Pulmon Dis* 12:561-69; Remih *et al.*, 2021 *Curr Opin Pharmacol* 59:149-56.

WVE-006 results in circulating AAT protein levels well above established 11 μM threshold *in vivo*

WVE-006 treatment results in serum AAT protein levels >11 uM in AATD mouse model (NSG-PiZ mice)



SERPINA1 mRNA editing in liver of AATD mouse model (NSG-PiZ mice, week 13)



WAVE LIFE SCIENCES

WVE-006 is a GalNAc-conjugated AIMer (A to I(G) RNA base editing oligonucleotide); WVE-006 administered in 7-week old NSG-PiZ mice (n=5 per group); Left: Total serum AAT protein quantified by ELISA; Stats: 2-way ANOVA with Dunnett post-hoc comparison to PBS ****<0.0001, *** <0.001; Right: Liver biopsies collected at week 13 (one week after last dose) and SERPINA1 editing was quantified by Sanger sequencing; Stats: 1-way ANOVA with Tukey post-hoc comparisons between all groups (only difference between dose groups shown) ns=non-significant

WVE-006 restores serum M-AAT protein in mice, increases serum neutrophil elastase inhibition

Correction of loss-of-function phenotypes



Restored M-AAT reaches lungs to protect from proteases





GalNAc-conjugated AIMers administered in 7-week old NSG-PiZ mice (n=5 per group). Proportion of AAT protein in serum measured by mass spec, total AAT protein quantified by ELISA. Serum collected from mice was tested for ability to inhibit fixed concentration of neutrophil elastase in an *in vitro* reaction. Stats: 2-way ANOVA with Bonferroni post-hoc for comparisons between PBS and WVE-006

WAVE LIFE SCIENCES

RNA editing preserves expression of *SERPINA1* transgene in liver of treated mice



Mutant mRNA;
***Wild-type* (edited) mRNA;**
Nucleus



GalNAc-conjugated AIMers administered in 7-week old NSG-PiZ mice (n=5 per group). mRNA expression quantified by qPCR. Stats: 1-way ANOVA with Dunnet post-hoc test for multiple comparisons

WVE-006 decreases lobular inflammation and PAS-D globule size, prevents increase in hepatocyte turnover

Correction of gain-of-function liver phenotypes

Fibrosis → Cirrhosis → Hepatocellular Carcinoma



Lobular inflammation
(NSG PiZ mice, week 13)



Mitoses
(NSG PiZ mice, week 13)



PAS-D-positive globule size
(NSG PiZ mice, week 13)



Left (Lobular inflammation) and Middle (Mitoses): Scatter plot showing inflammation grade or mitoses score. Each circle represents an individual mouse, (Mean ± SEM); Right (PAS-D Globule Size): 40 largest globules in each of 5 mice were measured. Each circle represents a single PAS-D globule, (Mean ± SEM). Baseline: week 0 (7 weeks old); Treated week 13 (20 weeks old); Stats: Kruskal-Wallis followed by Dunn's test

WAVE LIFE SCIENCES

WVE-006 supports dose-dependent RNA editing in human preclinical model systems

Efficient SERPINA1 editing in donor-derived primary human hepatocytes with WVE-006 (MZ genotype)



Note: Due to MZ genotype, Y-axis ranges from ~50-100%

Editing in iPSC-derived human hepatocytes with WVE-006 (ZZ genotype)







Primary human hepatocytes with MZ (left) or ZZ (right) genotype treated with WVE-006 at the indicated concentrations. Percentage editing was determined by Sanger sequencing.

WAVE LIFE SCIENCES

Conclusions

- We have developed RNA editing oligonucleotides – **AIMers** – intended to correct homozygous "*ZZ*" mutations to an "*MZ*" heterozygous state, and address both lung and liver phenotypes associated with AATD
- Investigational lead, WVE-006, drives serum AAT protein levels in AATD mouse model above 11 μM – the anticipated therapeutic threshold[1]
- Restored serum M-AAT inhibits neutrophil elastase, indicating the protein is functional and may protect lungs from damage
- Repeat dosing with WVE-006 reduces lobular inflammation and PAS-D globule size, and prevents increase in hepatocyte turnover in mouse liver
- WVE-006 supports dose-dependent RNA editing in human cellular models for AATD
- CTA submission for first-in-human study expected in 2H 2023

WAVE LIFE SCIENCES

[1]Brantly et al., 2018 *Chronic Obstr Pulm Dis*

Thanks to all colleagues and contributors from Wave Life Sciences and our collaborators

Check for updates

Endogenous ADAR-mediated RNA editing in non-human primates using stereopure chemically modified oligonucleotides

Prashant Monian[1,2], Chikdu Shivalila[1,2], Genliang Lu[1], Mamoru Shimizu[1], David Boulay[1], Karley Bussow[1], Michael Byrne[1], Adam Bezigian[1], Arindom Chatterjee[1], David Chew[1], Jigar Desai[1], Frank Favaloro[1], Jack Godfrey[1], Andrew Hoss[1], Naoki Iwamoto[1], Tomomi Kawamoto[1], Jayakanthan Kumarasamy[1], Anthony Lamattina[1], Amber Lindsey[1], Fangjun Liu[1], Richard Looby[1], Subramanian Marappan[1], Jake Metterville[1], Ronelle Murphy[1], Jeff Rossi[1], Tom Pu[1], Bijay Bhattarai[1], Stephany Standley[1], Snehlata Tripathi[1], Hailin Yang[1], Yuan Yin[1], Hui Yu[1], Cong Zhou[1], Luciano H. Apponi[1], Pachamuthu Kandasamy[1] and Chandra Vargeese[1] ✉

Technologies that recruit and direct the activity of endogenous RNA-editing enzymes to specific cellular RNAs have therapeutic potential, but translating them from cell culture into animal models has been challenging. Here we describe short, chemically modified oligonucleotides called AIMers that direct efficient and specific A-to-I editing of endogenous transcripts by endogenous adenosine deaminases acting on RNA (ADAR) enzymes, including the ubiquitously and constitutively expressed ADAR1 p110 isoform. We show that fully chemically modified AIMers with chimeric backbones containing stereopure phosphorothioate and nitrogen-containing linkages based on phosphoryl guanidine enhanced potency and editing efficiency 100-fold compared with those with uniformly phosphorothioate-modified backbones in vitro. In vivo, AIMers targeted to hepatocytes with *N*-acetylgalactosamine achieve up to 50% editing with no bystander editing of the endogenous *ACTB* transcript in non-human primate liver, with editing persisting for at least one month. These results support further investigation of the therapeutic potential of stereopure AIMers.

Recruiting endogenous RNA-editing enzymes using chemically modified oligonucleotides holds promise for treating human disease. The most common mutation in human genes is transition from cytosine (C) to thymine (T)[1], and CpG dinucleotides are well established hot spots for disease-causing mutations[2]. The ADAR family of enzymes catalyze adenine (A)-to-inosine (I) changes in the transcriptome[3–7]. Because I is read as guanine (G) by the translational machinery[8,9], ADAR-mediated RNA editing has the potential to revert these disease-causing transitions at the RNA level. The potential scope for application of A-to-I editing is large, including modulation of polar or charged amino acids, stop codons or RNA regulatory sequences[10,11], eliciting diverse functional outcomes (for example, restored protein expression or function)[11].

Chemical modifications are known to confer drug-like properties to oligonucleotides. We set out to determine whether control over backbone chemistry and stereochemistry and other chemical modifications to an oligonucleotide (Fig. 1 and Supplementary Note 1) can be optimized to elicit sequence-specific A-to-I RNA editing with endogenous ADAR enzymes. As therapeutics, reversible RNA editing with oligonucleotides may represent a safer option than those that edit genomic DNA[7]. Early technologies designed to elicit RNA editing in vitro required an exogenous enzyme and an oligonucleotide[12–17]. These approaches led to overexpression of editing enzyme and substantial off-target editing[12,14,16–18]. Recent advances have overcome the need for exogenous enzymes in vitro[18–20], but they still use long oligonucleotides that require ancillary delivery vehicles, such as viral vectors or lipid nanoparticles, for application beyond cell culture[7]. So far, these technologies have yielded nominal editing in vivo[18].

Leveraging our oligonucleotide chemistry platform, we developed relatively short oligonucleotides that elicit A-to-I RNA editing with high efficiency using endogenous ADAR enzymes. These oligonucleotides, called AIMers, are short and fully chemically modified with stereopure phosphorothioate (PS) and nitrogen-containing (PN) linkages based on phosphoryl guanidine. In vitro, they enhanced potency and A-to-I editing efficiency compared to uniformly PS-modified AIMers, and in vivo, *N*-acetylgalactosamine (GalNAc)-modified AIMers achieved up to 50% editing with no bystander editing in non-human primate (NHP) liver that persisted for at least 1 month.

Results

AIMers support RNA editing. To evaluate RNA-editing efficiency in mammalian cells, we created a luciferase reporter with genes from *Gaussia* (Gluc) and *Cypridinia* (Cluc). In the absence of editing, only Gluc is expressed, whereas A-to-I editing permits expression of Cluc, providing a measure of RNA-editing efficiency and protein expression (Extended Data Fig. 1a). AIMers were designed to mimic naturally occurring double-stranded RNA ADAR substrates, as in the GluR2 transcript[10,13,20] (Extended Data Fig. 1b).

To benchmark RNA editing, we transfected 293T cells with the reporter and exogenous ADAR enzyme in the presence or absence

[1]Wave Life Sciences, Cambridge, MA, USA. [2]These authors contributed equally: Prashant Monian, Chikdu Shivalila. ✉e-mail: cvargeese@wavelifesci.com

Preclinical RNA editing data published in *Nature Biotechnology* (March 2022)

- Foundational AIMer SAR
- GalNAc conjugation
- *In vitro-in vivo* translation (NHPs)
- Specificity *in vitro* & *in vivo* (NHPs)

WAVE
LIFE SCIENCES

Monian *et al.*, 2022 published online Mar 7, 2022; doi: 10.1038.s41587-022-01225-1
SAR structure-activity relationship